Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study

ConclusionThese results suggest that rituximab could be effective in EGPA vasculitis relapses. Mepolizumab is highly effective with a good safety profile in GC ‐dependent asthma. Our data suggest that 100 mg monthly could be an acceptable first‐line dose in selected instances of EGPA recognizing though that this has not been compared to the validated dose of 300 mg monthly.

Source: Arthritis and Rheumatology - September 30, 2020 Category: Rheumatology Authors: Alice Canzian, Nils Venhoff, Maria Letizia Urban, Silvia Sartorelli, Anne ‐Marie Ruppert, Matthieu Groh, Nicolas Girszyn, Camille Taillé, François Maurier, Vincent Cottin, Claire de Moreuil, Vincent Germain, Maxime Samson, Marie Jachiet, Tags: BRIEF REPORT Source Type: research